Radius Health

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.